Selecta Biosciences Inc. [NASDAQ: SELB] stock went on a downward path that fall over -4.45% on Friday, amounting to a one-week price increase of more than 0.31%. The company report on November 19, 2020 that AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia.
Gene therapy MMA-101 has obtained both orphan drug designation and rare pediatric disease designation from the FDA.
Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia (MMA) due to methylmalonyl-CoA mutase (MMUT) gene mutations. MMA-101 previously received rare pediatric disease designation from the FDA in October 2020.
Over the last 12 months, SELB stock rose by 101.25%. The average equity rating for SELB stock is currently 2.30, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $364.09 million, with 105.33 million shares outstanding and 79.95 million shares in the current float. Compared to the average trading volume of 2.91M shares, SELB stock reached a trading volume of 1085882 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Selecta Biosciences Inc. [SELB]:
William Blair have made an estimate for Selecta Biosciences Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on October 01, 2020. The new note on the price target was released on October 01, 2020, representing the official price target for Selecta Biosciences Inc. stock.
The Average True Range (ATR) for Selecta Biosciences Inc. is set at 0.21, with the Price to Sales ratio for SELB stock in the period of the last 12 months amounting to 32.22. Price to Free Cash Flow for SELB in the course of the last twelve months was 12.73 with Quick ratio for the last quarter at 2.20.
SELB Stock Performance Analysis:
Selecta Biosciences Inc. [SELB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.31. With this latest performance, SELB shares gained by 7.33% in over the last four-week period, additionally plugging by 28.29% over the last 6 months – not to mention a rise of 101.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SELB stock in for the last two-week period is set at 54.69, with the RSI for the last a single of trading hit 48.08, and the three-weeks RSI is set at 54.02 for Selecta Biosciences Inc. [SELB]. The present Moving Average for the last 50 days of trading for this stock 2.86, while it was recorded at 3.27 for the last single week of trading, and 2.78 for the last 200 days.
Insight into Selecta Biosciences Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Selecta Biosciences Inc. [SELB] shares currently have an operating margin of -785.61. Selecta Biosciences Inc.’s Net Margin is presently recorded at -828.97.
Return on Total Capital for SELB is now -240.39, given the latest momentum, and Return on Invested Capital for the company is -3,716.01. Return on Equity for this stock declined to -3,716.01, with Return on Assets sitting at -76.85. When it comes to the capital structure of this company, Selecta Biosciences Inc. [SELB] has a Total Debt to Total Equity ratio set at 229.57. Additionally, SELB Total Debt to Total Capital is recorded at 69.66, with Total Debt to Total Assets ending up at 19.36.
Reflecting on the efficiency of the workforce at the company, Selecta Biosciences Inc. [SELB] managed to generate an average of -$1,419,231 per employee. Receivables Turnover for the company is 2.67 with a Total Asset Turnover recorded at a value of 0.09.Selecta Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.20.
SELB Stock EPS
With the latest financial reports released by the company, Selecta Biosciences Inc. posted -0.28/share EPS, while the average EPS was predicted by analysts to be reported at -0.21/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SELB.
Selecta Biosciences Inc. [SELB] Insider Position Details
There are presently around $198 million, or 62.40% of SELB stock, in the hands of institutional investors. The top three institutional holders of SELB stocks are: BVF INC/IL with ownership of 8,459,547, which is approximately 1.989% of the company’s market cap and around 7.10% of the total institutional ownership; MANGROVE PARTNERS, holding 5,786,580 shares of the stock with an approximate value of $18.63 million in SELB stocks shares; and VANGUARD GROUP INC, currently with $15.05 million in SELB stock with ownership of nearly 26.395% of the company’s market capitalization.
Positions in Selecta Biosciences Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 38 institutional holders increased their position in Selecta Biosciences Inc. [NASDAQ:SELB] by around 7,056,002 shares. Additionally, 43 investors decreased positions by around 6,963,424 shares, while 15 investors held positions by with 47,472,601 shares. The mentioned changes placed institutional holdings at 61,492,027 shares, according to the latest SEC report filing. SELB stock had 14 new institutional investments in for a total of 1,495,523 shares, while 17 institutional investors sold positions of 2,226,572 shares during the same period.